Evoke Pharma, Inc.(EVOK)Earnings, Financials & Key Ratios
EVOK•NASDAQ
$11.00
$19M mkt cap·Price updated May 1, 2026
AboutEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Show more
- Revenue$10M+97.8%
- EBITDA$0+100.0%
- Net Income-$5M+31.3%
- EPS (Diluted)-2.81+90.0%
- Gross Margin96.52%+0.4%
- Operating Margin-50.78%+64.6%
- Net Margin-52.22%+65.3%
- ROE-240.09%+76.8%
- ROIC-608.46%-12.0%
- Debt/Equity0.73
- Interest Coverage-10.38+30.2%
EVOK Key Insights
Evoke Pharma, Inc. (EVOK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
EVOK Price & Volume
Evoke Pharma, Inc. (EVOK) stock price & volume — 10-year historical chart
Loading chart...
EVOK Growth Metrics
Evoke Pharma, Inc. (EVOK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years85.03%
TTM67.4%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM78.54%
Return on Capital
10 Years-180.96%
5 Years-213.34%
3 Years-167.93%
Last Year-228.28%
EVOK Peer Comparison
Evoke Pharma, Inc. (EVOK) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRPO | 53.07M | 30.40 | -10.38 | 5.05% | -5.83% | -9.12% | 0.10 | |
 AYTU | 15.51M | 2.47 | -1.14 | 1.84% | -39.02% | -172.12% | 1.21 | |
 TLSA | 192.14M | 1.51 | -6.86 | -8.69% | 0.03 | |||
 MBRX | 29.5M | 2.49 | -0.09 | -319.85% | 0.01 | |||
 ANIP | 1.78B | 83.91 | 25.27 | 43.78% | 8.87% | 14.49% | 0.60 | |
 HROW | 1.45B | 39.05 | -278.93 | 36.41% | -1.89% | -10.07% | 4.84 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 LPTX | 64.53M | 0.77 | 10.99 | 73.36% | 14.52% | 0.00 |
Compare EVOK vs Peers
Evoke Pharma, Inc. (EVOK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EVOK Income Statement
Evoke Pharma, Inc. (EVOK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 23.02K | 1.62M | 2.51M | 5.18M | 10.25M | 14.42M |
| Revenue Growth % | - | - | - | - | - | 6929% | 55.04% | 106.51% | 97.84% | 67.4% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 86.71K | 328.12K | 370.39K | 201.88K | 356.53K | 429.77K |
| COGS % of Revenue | - | - | - | - | 376.68% | 20.28% | 14.76% | 3.9% | 3.48% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -63.69K▲ 0% | 1.29M▲ 2125.3% | 2.14M▲ 65.8% | 4.98M▲ 132.8% | 9.89M▲ 98.7% | 13.99M▲ 0% |
| Gross Margin % | - | - | - | - | -276.68% | 79.72% | 85.24% | 96.1% | 96.52% | 97.02% |
| Gross Profit Growth % | - | - | - | - | - | 2125.31% | 65.76% | 132.84% | 98.7% | - |
| Operating Expenses | 10.54M | 11.23M | 8.01M | 7.15M | 12.98M | 9.44M | 9.92M | 12.41M | 15.1M | 19.19M |
| OpEx % of Revenue | - | - | - | - | 56401.64% | 583.51% | 395.61% | 239.54% | 147.3% | - |
| Selling, General & Admin | 3.59M | 4.09M | 3.92M | 3.74M | 6.43M | 8.85M | 9.62M | 12.23M | 15.08M | 19.13M |
| SG&A % of Revenue | - | - | - | - | 27927.16% | 547.02% | 383.62% | 236.03% | 147.14% | - |
| Research & Development | 6.95M | 7.14M | 4.1M | 3.42M | 6.55M | 590.48K | 300.79K | 181.91K | 16.32K | 16.32B |
| R&D % of Revenue | - | - | - | - | 28474.48% | 36.49% | 11.99% | 3.51% | 0.16% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1000K |
| Operating Income | -10.54M▲ 0% | -11.23M▼ 6.5% | -8.01M▲ 28.6% | -7.15M▲ 10.7% | -13.05M▼ 82.4% | -8.15M▲ 37.5% | -7.79M▲ 4.5% | -7.43M▲ 4.6% | -5.2M▲ 30.0% | -5.19M▲ 0% |
| Operating Margin % | - | - | - | - | -56678.32% | -503.79% | -310.37% | -143.44% | -50.78% | -35.99% |
| Operating Income Growth % | 10.78% | -6.51% | 28.64% | 10.73% | -82.37% | 37.52% | 4.48% | 4.56% | 29.97% | - |
| EBITDA | 0 | 0 | 0 | -7.13M | -13.04M | -8.04M | -7.72M | -7.29M | 0 | -4.73M |
| EBITDA Margin % | - | - | - | - | -56653.68% | -496.76% | -307.9% | -140.76% | - | -32.76% |
| EBITDA Growth % | 100% | - | - | - | -83.02% | 38.37% | 3.9% | 5.59% | 100% | -24.89% |
| D&A (Non-Cash Add-back) | 10.54M | 11.23M | 8.01M | 0 | 0 | 0 | 0 | 138.6K | 5.2M | 0 |
| EBIT | -10.48M | -12.23M | -7.57M | -7.13M | -13.04M | -8.04M | -7.72M | -7.29M | -4.85M | -4.73M |
| Net Interest Income | -268.03K | 0 | 0 | 28.8K | -107.32K | -491.44K | -437.99K | -361.4K | -148.06K | -34.15K |
| Interest Income | 0 | 0 | 15.21K | 28.8K | 5.67K | 8.62K | 62.01K | 138.6K | 353.31K | 465.85K |
| Interest Expense | 268.03K | 6.52K | 15.21K | 0 | 112.99K | 500.05K | 500K | 500K | 501.37K | 500K |
| Other Income/Expense | -204.11K | -998.83K | 448.61K | 28.8K | -107.32K | -386.31K | -437.99K | -361.4K | -148.06K | -34.15K |
| Pretax Income | -10.75M▲ 0% | -12.23M▼ 13.8% | -7.57M▲ 38.1% | -7.13M▲ 5.8% | -13.15M▼ 84.6% | -8.54M▲ 35.1% | -8.22M▲ 3.7% | -7.79M▲ 5.3% | -5.35M▲ 31.3% | -5.23M▲ 0% |
| Pretax Margin % | - | - | - | - | -57144.53% | -527.66% | -327.83% | -150.41% | -52.22% | -36.23% |
| Income Tax | 0 | -6.52K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0.05% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -10.75M▲ 0% | -12.23M▼ 13.8% | -7.57M▲ 38.1% | -7.13M▲ 5.8% | -13.15M▼ 84.6% | -8.54M▲ 35.1% | -8.22M▲ 3.7% | -7.79M▲ 5.3% | -5.35M▲ 31.3% | -5.23M▲ 0% |
| Net Margin % | - | - | - | - | -57144.53% | -527.66% | -327.83% | -150.41% | -52.22% | -36.23% |
| Net Income Growth % | 11.33% | -13.78% | 38.13% | 5.82% | -84.61% | 35.1% | 3.68% | 5.25% | 31.31% | 14.98% |
| Net Income (Continuing) | -10.75M | -12.23M | -7.57M | -7.13M | -13.15M | -8.54M | -8.22M | -7.79M | -5.35M | -5.23M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -165.75▲ 0% | -118.21▲ 28.7% | -65.62▲ 44.5% | -45.84▲ 30.1% | -74.91▼ 63.4% | -40.40▲ 46.1% | -31.16▲ 22.9% | -27.97▲ 10.2% | -2.81▲ 90.0% | -2.04▲ 0% |
| EPS Growth % | 38.41% | 28.68% | 44.49% | 30.14% | -63.42% | 46.07% | 22.87% | 10.24% | 89.95% | 78.54% |
| EPS (Basic) | -165.75 | -118.21 | -65.62 | -45.84 | -74.91 | -40.40 | -31.16 | -27.97 | -2.81 | - |
| Diluted Shares Outstanding | 64.85K | 103.46K | 115.29K | 154.83K | 177.03K | 223.51K | 261.97K | 278.56K | 1.91M | 2.56M |
| Basic Shares Outstanding | 64.85K | 103.46K | 115.29K | 154.83K | 177.03K | 223.51K | 261.97K | 278.56K | 1.91M | 2.56M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EVOK Balance Sheet
Evoke Pharma, Inc. (EVOK) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.28M | 7.93M | 5.65M | 6.25M | 9.28M | 10.56M | 11.72M | 6.83M | 17.24M | 15.54M |
| Cash & Short-Term Investments | 9.01M | 7.68M | 5.32M | 5.66M | 8.07M | 9.14M | 9.84M | 4.74M | 13.6M | 11.58M |
| Cash Only | 9.01M | 7.68M | 5.32M | 5.66M | 8.07M | 9.14M | 9.84M | 4.74M | 13.6M | 11.58M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 23.31K | 295.19K | 624.83K | 673.07K | 2.42M | 3.19M |
| Days Sales Outstanding | - | - | - | - | 369.61 | 66.59 | 90.91 | 47.42 | 86.19 | 69.76 |
| Inventory | 0 | 0 | 0 | 0 | 236.48K | 185.53K | 289.38K | 481.84K | 445.08K | 599.91K |
| Days Inventory Outstanding | - | - | - | - | 995.42 | 206.39 | 285.16 | 871.17 | 455.65 | 471.15 |
| Other Current Assets | 8K | 0 | 0 | 0 | 30.3K | 11.55K | 11.55K | 47.53K | 43.9K | 33.71K |
| Total Non-Current Assets | 11.55K | 11.55K | 11.55K | 150.09K | 153.26K | 12.43K | 129.07K | 241.64K | 281.11K | 113.03K |
| Property, Plant & Equipment | 0 | 0 | 0 | 138.54K | 141.71K | 12.43K | 129.07K | 0 | 154.18K | 106.71K |
| Fixed Asset Turnover | - | - | - | - | 0.16x | 130.20x | 19.44x | - | 66.48x | 110.41x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 11.55K | 11.55K | 11.55K | 11.55K | 11.55K | 0 | 0 | 241.64K | 126.93K | 145.86K |
| Total Assets | 9.29M▲ 0% | 7.94M▼ 14.6% | 5.66M▼ 28.7% | 6.4M▲ 13.0% | 9.43M▲ 47.5% | 10.57M▲ 12.1% | 11.85M▲ 12.1% | 7.07M▼ 40.4% | 17.52M▲ 147.8% | 15.65M▲ 0% |
| Asset Turnover | - | - | - | - | 0.00x | 0.15x | 0.21x | 0.73x | 0.59x | 0.88x |
| Asset Growth % | -2.5% | -14.55% | -28.73% | 13% | 47.51% | 12.07% | 12.09% | -40.36% | 147.84% | 222.24% |
| Total Current Liabilities | 1.41M | 2.07M | 1.63M | 2.02M | 7.54M | 1.41M | 1.65M | 9.65M | 10.38M | 12.24M |
| Accounts Payable | 478.22K | 1.05M | 476.2K | 1.03M | 1.27M | 874.03K | 868.31K | 1.71M | 2.04M | 3.92M |
| Days Payables Outstanding | - | - | - | - | 5.36K | 972.27 | 855.67 | 3.09K | 2.09K | 2.62K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 104.17K | 0 | 0 | 5M | 5M | 5.07M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 1 | 5M | 519.32K | 66K | 1.32M | 100K | 2.49M |
| Current Ratio | 6.58x | 3.82x | 3.46x | 3.10x | 1.23x | 7.51x | 7.08x | 0.71x | 1.66x | 1.66x |
| Quick Ratio | 6.58x | 3.82x | 3.46x | 3.10x | 1.20x | 7.38x | 6.91x | 0.66x | 1.62x | 1.62x |
| Cash Conversion Cycle | - | - | - | - | -4K | -699.3 | -479.59 | -2.18K | -1.55K | -2.08K |
| Total Non-Current Liabilities | 4.1M | 3.7M | 0 | 0 | 5.11M | 5.61M | 6.11M | 0 | 100.96K | 46.38K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 5M | 5M | 5M | 5M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100.96K | 295.58K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4.1M | 3.7M | 0 | 0 | 112.99K | 612.29K | 1.11M | -5M | 0 | 0 |
| Total Liabilities | 5.51M | 5.78M | 1.63M | 2.02M | 12.65M | 7.02M | 7.77M | 9.65M | 10.48M | 12.29M |
| Total Debt | 0 | 0 | 0 | 138.54K | 5.25M | 5.01M | 5.13M | 10M | 5.16M | 5.11M |
| Net Debt | -9.01M | -7.68M | -5.32M | -5.53M | -2.82M | -4.13M | -4.71M | 5.26M | -8.44M | -6.46M |
| Debt / Equity | - | - | - | 0.03x | - | 1.41x | 1.26x | - | 0.73x | 0.73x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.08x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.37x |
| Interest Coverage | -39.34x | -1722.76x | -526.83x | - | -115.47x | -16.30x | -15.57x | -14.86x | -10.38x | -9.45x |
| Total Equity | 3.79M▲ 0% | 2.17M▼ 42.8% | 4.03M▲ 85.9% | 4.38M▲ 8.8% | -3.21M▼ 173.4% | 3.56M▲ 210.6% | 4.08M▲ 14.9% | -2.58M▼ 163.2% | 7.04M▲ 372.8% | 3.36M▲ 0% |
| Equity Growth % | 9.31% | -42.82% | 85.86% | 8.82% | -173.38% | 210.59% | 14.9% | -163.15% | 372.84% | 480.65% |
| Book Value per Share | 58.41 | 20.93 | 34.91 | 28.29 | -18.16 | 15.91 | 15.59 | -9.26 | 3.69 | 1.31 |
| Total Shareholders' Equity | 3.79M | 2.17M | 4.03M | 4.38M | -3.21M | 3.56M | 4.08M | -2.58M | 7.04M | 3.36M |
| Common Stock | 1.24K | 1.54K | 1.74K | 2.44K | 2.66K | 272 | 334 | 28 | 149 | 172 |
| Retained Earnings | -58.81M | -71.04M | -78.6M | -85.73M | -98.89M | -107.42M | -115.65M | -123.44M | -128.79M | -132.82M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EVOK Cash Flow Statement
Evoke Pharma, Inc. (EVOK) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.71M | -8.72M | -6.98M | -5.76M | -6.63M | -12.35M | -6.6M | -4.98M | -5.46M | -5.46M |
| Operating CF Margin % | - | - | - | - | -28801.07% | -763.43% | -262.93% | -96.22% | -53.26% | - |
| Operating CF Growth % | 17.04% | -0.11% | 19.94% | 17.43% | -15.06% | -86.32% | 46.6% | 24.42% | -9.5% | 116.61% |
| Net Income | -10.75M | -12.23M | -7.57M | -7.13M | -13.15M | -8.54M | -8.22M | -7.79M | -5.35M | -5.23M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.71M | 1.82M | 1.54M | 1.37M | 1.63M | 1.88M | 1.46M | 0 | 773.12K | 188.64K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 56.97K | 1.01M | -433.39K | 0 | 0 | -75.13K | 37.02K | 1.26M | 518.05K | 940.11K |
| Working Capital Changes | 277.3K | 687.83K | -518.56K | -10.4K | 4.9M | -5.62M | 132.41K | 1.55M | -1.4M | 772.86K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | -271.88K | -329.64K | -48.24K | -1.75M | -1.17M |
| Change in Inventory | 0 | 0 | 0 | 0 | -236.48K | 20.95K | -103.84K | -192.46K | 32.84K | -110.42K |
| Change in Payables | -276.71K | 663.16K | -440.38K | 106.28K | 243.36K | -527.86K | 60.28K | 655.13K | 751.75K | 1.93M |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | 0% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 9.02M | 7.39M | 4.62M | 6.11M | 9.04M | 13.43M | 7.29M | -119.3K | 14.32M | 3.56M |
| Debt Issued (Net) | -4.5M | 0 | 0 | 0 | 5.1M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | -119.3K | 1000K | 1.06M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -191 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 335.23K | -1.27M | 7.29M | 0 | 7.6M | 0 |
| Net Change in Cash | 315.92K▲ 0% | -1.33M▼ 520.3% | -2.36M▼ 77.8% | 344.83K▲ 114.6% | 2.41M▲ 597.5% | 1.08M▼ 55.3% | 698.99K▼ 35.0% | -5.1M▼ 830.2% | 8.86M▲ 273.5% | 236.98K▲ 0% |
| Free Cash Flow | -8.71M▲ 0% | -8.72M▼ 0.1% | -6.98M▲ 19.9% | -5.76M▲ 17.4% | -6.63M▼ 15.1% | -12.35M▼ 86.3% | -6.6M▲ 46.6% | -4.98M▲ 24.4% | -5.46M▼ 9.5% | -3.32M▲ 0% |
| FCF Margin % | - | - | - | - | -28801.07% | -763.43% | -262.93% | -96.22% | -53.26% | -23.05% |
| FCF Growth % | 17.04% | -0.11% | 19.94% | 17.43% | -15.06% | -86.32% | 46.6% | 24.42% | -9.5% | 37.57% |
| FCF per Share | -134.28 | -84.26 | -60.53 | -37.21 | -37.45 | -55.27 | -25.18 | -17.90 | -2.87 | -2.87 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.71x | 0.92x | 0.81x | 0.50x | 1.45x | 0.80x | 0.64x | 1.02x | 0.64x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EVOK Key Ratios
Evoke Pharma, Inc. (EVOK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -296.41% | -410.84% | -244.42% | -169.54% | -2256.53% | -5015.38% | -215.3% | -1035.44% | -240.09% | -155.44% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | -543.44% | -608.46% | -608.46% |
| Gross Margin | - | - | - | - | -276.68% | 79.72% | 85.24% | 96.1% | 96.52% | 97.02% |
| Net Margin | - | - | - | - | -57144.53% | -527.66% | -327.83% | -150.41% | -52.22% | -36.23% |
| Debt / Equity | - | - | - | 0.03x | - | 1.41x | 1.26x | - | 0.73x | 0.73x |
| Interest Coverage | -39.34x | -1722.76x | -526.83x | - | -115.47x | -16.30x | -15.57x | -14.86x | -10.38x | -9.45x |
| FCF Conversion | 0.81x | 0.71x | 0.92x | 0.81x | 0.50x | 1.45x | 0.80x | 0.64x | 1.02x | 0.64x |
| Revenue Growth | - | - | - | - | - | 6929% | 55.04% | 106.51% | 97.84% | 67.4% |
EVOK Frequently Asked Questions
Evoke Pharma, Inc. (EVOK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Evoke Pharma, Inc. (EVOK) reported $14.4M in revenue for fiscal year 2024.
Evoke Pharma, Inc. (EVOK) grew revenue by 97.8% over the past year. This is strong growth.
Evoke Pharma, Inc. (EVOK) reported a net loss of $5.2M for fiscal year 2024.
Dividend & Returns
Evoke Pharma, Inc. (EVOK) has a return on equity (ROE) of -240.1%. Negative ROE indicates the company is unprofitable.
Evoke Pharma, Inc. (EVOK) had negative free cash flow of $3.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More EVOK
Evoke Pharma, Inc. (EVOK) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates